{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Progressive disease (PD)/failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Stable disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Not evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Stage 2 did not open for enrollment.","groups":[{"description":"panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every week, as part of a 28-day treatment cycle. Group X indications (AML, CML-BC, AP, CP, ALL, MDS (RAEB-1, -2), MMM, CMML, aCML, CLL, and PLL) is a sub-arm, based on disease indication.","id":"OG000","title":"Arm 1, Group X"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set. Response as per investigator assessment for a subset of patients with AML accrued in the expansion phase (IA) include complete response, progressive disease/failure, stable disease.","reportingStatus":"POSTED","timeFrame":"1.2 years","title":"Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) in Expansion Phase","type":"SECONDARY","unitOfMeasure":"Participants"}